Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1996, Pages 259-266

  Nohynek, G J ^a   Plard, J P ^a   Wells, M Y ^a   Zerial, A ^a   Roquet, F ^a  

^a SANOFI   (France)

Author keywords

CD rats; rHuG CSF

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MANUFACTURE; ERYTHROCYTE COUNT; ESCHERICHIA COLI; GLYCOSYLATION; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0031060228     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050570     Document Type: Article

References (23)

1. Asano S (1991) Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol 13: 400-413
2. Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC, Chazin VR, Bruszewski J, Lu H, Chen KK, Barendt J, Platzer E, Moore MAS, Mertelsmann R, Welte K (1986) Recombinant human granulocyte colony-stimulating factor. Effects on normal and myeloid leukemic cells. Science 232: 61-65
3. Oheda M, Hase S, Ono M, Ikenaka T (1988) Structures of the sugar chains of recombinant human granulocyte colony-stimulating factor produced by Chinese hamster ovary cells. J Biochem 103: 544-546
4. Bodensteiner DC, Doolittle GC (1993) Adverse haematological complications of anticancer drugs. Drug Safety 8: 213-224
5. Hollingshead LM, Goa KL (1991) Recombinant granulocyte colony-stimulating factor (rHuC-GSF) A review of its pharmacological properties and prospective role in neutropenic conditions. Drugs 42: 300-330
6. Frampton JE, Lee CR, Faulds D (1994) Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 48: 731-760
7. Bonadonna G, Linch D, Prugnaud JL (eds) (1994) Lenograstim: the first glycosylated human recombinant granulocyte colony-stimulating factor: its role in cancer treatment. Eur J Cancer 30A [Suppl 3]
8. Oh-eda M, Hasegawa M, Hattori K, Kuboniwa H, Kojima, T, Orita T, Tomonou K, Yamazaki T, Ochi M (1990) O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation, allowing it to retain its biological activity. J Biol Chem 265: 111432-111435
9. Kishita M, Motojima H, Oheda M, et al (1992) Stability of granulocyte colony-stimulating factor (G-CSF) in serum. Clin Rep 26: 221-224
10. Nissen C, Dalle Carbonare V, Moser Y (1994) In vitro comparison of the biological potency of glycosylated versus nonglycosylated rHuC-GSF. Drug Invest 7: 346-352
11. Gabrilove JL, Jakubowski A, Fain K, et al (1988) Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest 82: 1454-1461
12. Rhone-Poulenc Rorer (1995) Comparison of the activity on granulopoiesis of filgrastim and lenograstim in CD rats. Preliminary study. RPR/RD/CRVA/SM 95-0034 (unpublished report). Rhone-Poulenc Rorer, F-94403 Vitry-sur-Seine, France
13. Ono M (1994) Physicochemical and biochemical characteristics of glycosylated recombinant granulocyte colony stimulating factor (lenograstim). Eur J Cancer 30A [Suppl 3]: S7-S11
14. Monroy RL, Skelly RR, Taylor P, Dubois A, Donahue RE, MacVittie TJ (1988) Recovery from severe hematopoietic suppression using recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 16: 344-348
15. Lindemann A, Herrmann F, Oster W, Haffner W, Meyenburg W, Souza LM, Mertelsmann R (1989) Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. Blood 74: 2644-2651
16. Mire-Sluis AR, Gaines Das R, Thorpe R (1995) Immunological standardization. The international standard for granulocyte colony stimulating factor (G-CSF). Evaluation in an international collaborative study. J Immunol Methods 179: 117-126
17. Keller AU, Smalling R (1993) Granulocyte colony stimulating factor: animal studies for risk assessment. Int Rev Exp Pathol 34: 173-188
18. Frampton JE, Yarker YE, Goa KL (1995) Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings. Drugs 49: 767-793
19. Rhone-Poulenc Rorer (1995) RP 12453 (cyclophosphamide): leukopenic activity after a single intraperitoneal administration to CD rats. Range-finding study. RPR/RD/CRVA/SM 95-0202 (unpublished report). Rhone-Poulenc Rorer, F-94403 Vitry-sur-Seine, France
20. Höglund M, Bengtsson M, Cour-Chabernaud V, Dabouz-Harrouche F, Simonsson B, Smedmyr B, Töttermann T (1995) Glycosylated rHuG-CSF is more potent than nonglycosylated rHuG-CSF in mobilisation of peripheral blood progenitor cells (PBPC) in healthy volunteers. Blood 86 [Suppl 1]: 464a
21. Yushino T, Tamura H, Hattori K, Kawamura A, Imai N, Ono M (1991) Effects of recombinant human granulocyte colony-stimulating factor on neutrophil function in normal rats. Int J Hematol 54: 455-462
22. Berger J (1990) Leucokinetic study. Morphology of the bone marrow after experimental induction of marrow hyperplasia by cyclophosphamide in laboratory rats. Z Klin Bluttorsch 107: 862-877
23. Wheeler AG, Dansby D, Hawkins HC, Payne HG, Weikel JH Jr (1962) A toxicologic and hematologic evaluation of cyclophosphamide (Cytoxan) in experimental animals. Toxicol Appl Pharmacol 4: 324-343